Search results
Results from the WOW.Com Content Network
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), [10] [11] and immunoglobulin E-mediated food allergy.
These drugs are used for the treatment of asthma. They may be useful either in the treatment or prevention of asthma attacks. ... Anti-asthmatic agent; B ...
Zafirlukast is FDA-approved for the prevention and treatment of asthma in adults and children older than 5 years old. [1] Like other leukotriene receptor antagonists, zafirlukast is thought to be useful for the long-term treatment of asthma, but it is generally less effective than inhaled glucocorticoids as monotherapy (which are the standard of care) or long-acting beta-2 agonists in ...
[2] [1] Fixed-dose combinations of theophylline and ephedrine were abandoned after the 1970s as they did not allow for dose titration in asthma therapy owing to the toxicity of ephedrine. [ 19 ] The effects of theophylline/ephedrine as a performance-enhancing drug in exercise and sports have been studied.
This drug prevents the release of inflammatory chemicals such as histamine from mast cells. It is considered a breakthrough drug in management of asthma, as the patients can be freed from steroids in many cases; however, it is mainly effective as a prophylaxis for allergic and exercise-induced asthma, not as a treatment for acute asthma attacks.
The proposed mechanism is that while LABAs relieve asthma symptoms, they can also promote bronchial inflammation and sensitivity without warning. [23] On February 18, 2011, the FDA issued a safety alert for long-acting β agonists. [24]
In March 2016, the US Food and Drug Administration (FDA) approved reslizumab (Cinqair) for use with other asthma medicines for the maintenance treatment of severe asthma in people aged 18 years and older. [7] It is approved for people who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. [7]